

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1134R2C2

Serial No.

09/896,096

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

1646

To Be Assigned

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
Cm	*	1	4,179,337	18.12.79	Davis et al.		
	*	2	4,301,144	17.11.81	Iwashita et al.		
	*	3	4,399,216	16.08.83	Axel et al.		
	*	4	4,496,689	29.01.85	Mitra, G.		
	*	5	4,640,835	03.02.87	Shimizu et al.		
	*	6	4,670,417	02.06.87	Iwasaki et al.		
	*	7	4,676,980	30.06.87	Segal et al.		
	*	8	4,736,866	12.04.88	Leder et al.		
	*	9	4,791,192	13.12.88	Nakagawa et al.		
	*	10	4,816,567	28.03.89	Cabilly et al.		
	*	11	4,870,009	26.09.89	Evans et al.		
	*	12	5,010,182	23.04.91	Brake et al.		
	*	13	5,364,934	15.11.94	Drayna et al.		
	*	14	5,447,851	05.09.95	Beutler et al.		
	*	15	5,885,800	23.03.99	Emery et al.		
	*	16	60/035,496				14.01.97
	*	17	60/035,722				28.01.97
	*	18	60/037,829				05.02.97
	*	19	60/079,856	Dou et al.			30.03.98
	*	20	60/086,074	Dou et al.			20.05.98
	*	21	60/099,643	Dou et al.			09.09.98
	*	22	60/112,577	Dou et al.			17.12.98
	*	23	60/112,703	Dou et al.			18.12.98
	*	24	60/112,933	Dou et al.			18.12.98
	*	25	60/113,407	Dou et al.			22.12.98

RECEIVED  
JAN 22 2002  
TECH CENTER 1600/2900

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
Cm	*	26	0,003,089 A1	25.07.79	EPO (ENGLISH ABSTRACT ATTACHED)			
	*	27	036,776 A2	30.09.81	EPO			
	*	28	073,657	09.03.83	EPO			
	*	29	117,058 A2	29.08.84	EPO			
	*	30	117,060 A2	29.08.84	EPO			
	*	31	307,247 B1	15.03.89	EPO			
	*	32	362,179 A2	04.04.90	EPO			
	*	33	417,563 B1	20.03.91	EPO (ENGLISH ABSTRACT ATTACHED)			

Examiner

Cm

Date Considered

9/20/02

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1134R2C2

Serial No.

09/896,096

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

16.46  
To Be Assigned

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
cu	* 34	861,850	02.09.98	EPO			
	* 35	19,809,978	16.09.99	GERMANY			
	* 36	WO 00/32221	08.06.00	PCT			
	* 37	WO 00/52028	08.09.00	PCT			
	* 38	WO 00/53758	14.09.00	PCT			
	* 39	WO 00/58465	05.10.00	PCT			
	* 40	WO 00/58466	05.10.00	PCT			
	* 41	WO 87/05330	11.09.87	PCT			
	* 42	WO 89/05859	29.06.89	PCT			
	* 43	WO 90/13646	15.11.90	PCT (ENGLISH ABSTRACT ATTACHED)			
	* 44	WO 91/00360	10.01.91	PCT			
	* 45	WO 92/20373	26.11.92	PCT			
	* 46	WO 93/08829	13.05.93	PCT			
	* 47	WO 97/23614	03.07.97	PCT			
	* 48	WO 97/25428	17.07.97	PCT			
	* 49	WO 98/30694	16.07.98	PCT			
	* 50	WO 98/32856	30.07.98	PCT			
	* 51	WO 99/04001	28.01.99	PCT			
	* 52	WO 99/07738	18.02.99	PCT			
	* 53	WO 99/11791	11.03.99	PCT			
	* 54	WO 99/14330	25.03.99	PCT			
	* 55	WO 99/26977	03.06.99	PCT			
	* 56	WO 99/31128	24.06.99	PCT			
	* 57	WO 99/50413	10.07.99	PCT			
cu	* 58	2,211,504	05.07.89	UNITED KINGDOM			

RECEIVED  
JAN 22 2002  
TECH CENTER 1600/2900

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

cu	* 59	Altschul et al., "Local alignment statistics" <u>Methods in Enzymology</u> 266:460-480 (1996)
	* 60	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-induced Death of Developing T Cells" <u>Cold Spring Harbor Laboratory Symposium on Programmed Cell Death</u> (Abstr. No. 10) (1995)
	* 61	Anderson et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function" <u>Nature</u> 390(6656):175-179 (Nov 13, 1997)
	* 62	Anderson, W.F., "Human gene therapy" <u>Science</u> 256(5058):808-813 (May 8, 1992)
	* 63	Aplin and Wriston, "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids" <u>CRC Crit. Rev. Biochem.</u> 10(4):259-306 (1981)
cu	* 64	Arase et al., "Fas-mediated cytotoxicity by freshly isolated natural killer cells" <u>Journal of Experimental Medicine</u> 181(3):1235-1238 (Mar 1, 1995)

Examiner

Clara M. Koz

Date Considered

9/20/02

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1134R2C2

Serial No.

09/896,096

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

1646  
~~To Be Assigned~~

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

cr	* 65	Ashkenazi and Chamow, "Immunoadhesins: An Alternative to Human Monoclonal Antibodies" <u>Methods: A Companion to Methods in Enzymology</u> 8:104-115 (1995)
	* 66	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991)
	* 67	Bai et al., "Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster" <u>Proc. Natl. Acad. Sci.</u> 97:1230-1235 (2000)
	* 68	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF $\beta$ Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)
	* 69	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" <u>Immunity</u> 6:79-88 (1997)
	* 70	Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" <u>The Journal of Immunology</u> 147(1):86-95 (1991)
	* 71	Bolivar et al., "Construction and Characterization of New Cloning Vehicles. II. A Multipurpose Cloning System" <u>Gene</u> 2:95-113 (1977)
	* 72	Bradley, "Production and Analysis of Chimaeric Mice" <u>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</u> , E. J. Robertson, ed., IRL, Oxford, Chapter 5, pps. 113-151 (1987)
	* 73	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990)
	* 74	Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 51-63 (1987)
	* 75	Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" <u>Cell</u> 87:845-855 (1996)
	* 76	Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (1985)
cr	* 77	Chang et al., "Phenotypic Expression in E. coli of a DNA Sequence Coding for Mouse Dihydrofolate Reductase" <u>Nature</u> 275:617-624 (October 19, 1978)
	* 78	<del>Chemotherapy Service Ed., M.C. Perry, Baltimore, MD:Williams &amp; Wilkins (1992)</del>
cr	* 79	Chicheportiche et al., "TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis" <u>Journal of Biological Chemistry</u> 272(51):32401-32410 (1997)
	* 80	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996)
	* 81	Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>Journal Mol. Biol.</u> 105:1-14 (1976)
cr	* 82	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , New York:Alan R. Liss, Inc. pps. 77-96 (1985)
	* 83	<del>Coligan et al., Current protocols in immunology, New York:John Wiley &amp; Sons (1994)</del>
cr	* 84	Creighton, "Protein Biosynthesis" <u>Proteins: Structures and Molecular Principles</u> , San Francisco:W.H. Freeman & Co. pps. 79-86 (1983)

Examiner

*Clare M. King*

Date Considered

9/20/02

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1134R2C2

Serial No.

09/896,096

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

1646  
~~No De Assigned~~

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Cu	* 85	David et al., "Protein Iodination with Solid State Lactoperoxidase" <u>Biochemistry</u> 13(5):1014-1021 (1974)
	* 86	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon- $\gamma$ " <u>European Journal of Immunology</u> 17:689-693 (1987)
	* 87	deBoer et al., "The TAC Promoter: A functional Hybrid Derived From the TRP and LAC Promoters" <u>Proc. Natl. Acad. Sci. USA</u> 80:21-25 (1983)
	* 88	Deutscher, M., "Rethinking your purification procedure" <u>Methods in Enzymology</u> 182:779-780 (1990)
Cu	* 89	Dhein et al., "Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)" <u>Nature</u> 373(6513):438-441 (Feb 2, 1995)
	* 90	<del>Dreffenbach et al., PCR-Primer: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1995)</del>
Cu	* 91	Dzau et al., "Gene therapy for cardiovascular disease" <u>Trends in Biotechnology</u> 11:205-210 (1993)
	* 92	Edge et al., "Deglycosylation of glycoproteins by trifluoromethanesulfonic acid" <u>Analytical Biochemistry</u> 118:131-137 (1981)
	* 93	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular &amp; Cellular Biology</u> 5:3610-3616 (1985)
	* 94	Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from <i>Saccharomyces cerevisiae</i> by Use of an Epitope Addition Method" <u>Molecular &amp; Cellular Biology</u> 8:2159-2165 (1988)
	* 95	Gelb et al., "Pycnodysostosis: Refined Linkage and Radiation Hybrid Analyses Reduce the Critical Region to 2 cM at 1q21 and Map Two Candidate Genes" <u>Human Genet.</u> 98:141-144 (1996)
	* 96	Gelmini et al., "Quantitative polymerase chain reaction-based homogeneous assay with fluorogenic probes to measure c-erbB-2 oncogene amplification" <u>Clinical Chemistry</u> 43(5):752-758 (May 1997)
	* 97	Gething and Sambrook, "Cell-surface Expression of Influenza Haemagglutinin from a Cloned DNA Copy of the RNA Gene" <u>Nature</u> 293:620-625 (October 22, 1981)
	* 98	Goding, "Production of Monoclonal Antibodies" <u>Monoclonal Antibodies: Principles and Practice</u> , Academic Press, pps. 59-103 (1986)
	* 99	Goeddel et al., "Direct Expression in <i>Escherichia coli</i> of a DNA Sequence Coding for Human Growth Hormone" <u>Nature</u> 281:544-548 (October 18, 1979)
	*100	Goeddel et al., "Synthesis of Human Fibroblast Interferon by <i>E. coli</i> " <u>Nucleic Acids Research</u> 8(18):4057-4074 (1980)
	*101	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" <u>Molecular &amp; Cellular Biology</u> 11:3020-3026 (1991)
	*102	Graham and van der Eb, "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA" <u>Virology</u> 52:456-467 (1973)
	*103	Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" <u>J. Gen. Virol.</u> 36:59-74 (1977)
Cu	*104	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <u>Blood</u> 85:3378-3404 (1995)

Examiner

Chen M. J.

Date Considered

9/20/04

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


RECEIVED

JAN 22 2002

TECH CENTER 1600/2900

USCOMM-DC 80-398

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1134R2C2

Serial No.

09/896,096

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

1646  
To Be Assigned

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

cu	*105	Hahne et al., "Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape" <u>Science</u> 274(5291):1363-1366 (Nov 22, 1996)
	*106	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in E. coli" <u>J. Cell. Biochem.</u> (abstract only Supplement 15F; P 424) pps. 113 (1991)
	*107	<u>Handbook of Monoclonal Antibodies</u> , Ferrone et al. eds., Park Ridge, NJ:Noyes Publications, pps. 302-359 and Chapter 22 (1985)
	*108	Hess et al., "Cooperation of Glycolytic Enzymes" <u>Advances in Enzyme Regulation</u> , George Weber, New York:Pergamon Press Vol. 7:149-167 (1968)
	*109	Hitzeman et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique" <u>Journal of Biological Chemistry</u> 255(24):12073-12080 (December 25, 1980)
	*110	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF $\alpha$ )" <u>Journal of Biological Chemistry</u> 264(25):14927-14934 (1989)
	*111	Holland and Holland, "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase" <u>Biochemistry</u> 17(23):4900-4907 (1978)
	*112	Holmes et al., "Structure and Functional Expression of a Human Interleukin-8 Receptor" <u>Science</u> 253(5025):1278-1280 (1991)
	*113	Hoogenboom and Winter, "By-passing immunisation: human antibodies from synthetic repertoires of germline V $\mu$ gene segments rearranged in vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)
	*114	Hopp et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification" <u>Bio/Technology</u> 6:1204-1210 (1988)
	*115	Hsiao and Carbon, "High-frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast Arg4 Gene" <u>Proc. Natl. Acad. Sci. USA</u> 76:3829-3833 (1979)
	*116	Hunter et al., "Preparation of Iodine 131 Labelled Human Growth Hormone of High Specific Activity" <u>Nature</u> 194:495-496 (1962)
	*117	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" <u>Cell</u> 66:233-243 (1991)
	*118	Johnson et al., "Expression and Structure of the Human NGF Receptor" <u>Cell</u> 47:545-554 (1986)
	*119	Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)
	*120	Jones, E., "Proteinase Mutants of <i>Saccharomyces Cerevisiae</i> " <u>Genetics</u> 85(1):23-33 (1977)
	*121	Keown et al., "Methods for Introducing DNA into Mammalian Cells" <u>Methods in Enzymology</u> 185:527-537 (1990)
	*122	Kingsman et al., "Replication in <i>Saccharomyces Cerevisiae</i> of Plasmid pBR313 Carrying DNA from the Yeast trp1 Region" <u>Gene</u> 7:141-152 (1979)
	*123	Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" <u>Nature</u> 384:372-375 (1996)
cu	*124	Kohler and Milstein, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <u>Nature</u> 256:495-497 (August 7, 1975)

Examiner

Date Considered

9/20/02

RECEIVED

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JAN 22 2002

TECH CENTER 1600/2900

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1134R2C2

Serial No.

09/896,096

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

1646  
~~To Be Assigned~~

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

cu	*125	Kohn et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)
	*126	Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" <u>The Journal of Immunology</u> 133(6):3001-3005 (1984)
	*127	Krammer et al., "Regulation of Apoptosis in the Immune System" <u>Curr. Op. Immunol.</u> 6:279-289 (1994)
	*128	Kwon et al., "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer" <u>Proc. Natl. Acad. Sci. USA</u> 94(15):8099-8103 (Jul 22, 1997)
	*129	Lacey et al., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation" <u>Cell</u> 93(2):165-176 (Apr 17, 1998)
	*130	Leach et al., "Enhancement of antitumor immunity by CTLA-4 blockade" <u>Science</u> 271(5256):1734-1736 (Mar 22, 1996)
	*131	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" <u>Proc. Natl. Acad. Sci. USA</u> 88:2830-2834 (1991)
	*132	Li et al., "Targeted mutation of the DNA methyltransferase gene results in embryonic lethality" <u>Cell</u> 69:915-926 (1992)
	*133	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (1990)
	*134	Lutz-Freyermuth et al., "Quantitative Determination That One of Two Potential RNA-binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-loop II of U1 RNA" <u>Proc. Natl. Acad. Sci. USA</u> 87:6393-6397 (1990)
cu	*135	Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9:1063-1068 (1990)
	*136	<del>Mammalian Cell Biotechnology: A Practical Approach; M. Butler, ed., IRL Press (1991)</del>
cu	*137	Mansour et al., "Disruption of the Proto-oncogene int-2 in Mouse Embryo-derived Stem Cells: a General Strategy for Targeting Mutations to Non-selectable Genes" <u>Nature</u> 336:348-352 (1988)
	*138	Mantel et al., "Rabbit $\beta$ -globin mRNA Production in Mouse L Cells Transformed with Cloned Rabbit $\beta$ -globin Chromosomal DNA" <u>Nature</u> 281:40-46 (September 6, 1979)
	*139	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)
	*140	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA" <u>Current Biology</u> 6(6):750-752 (1996)
	*141	Marsters et al., "Apo-3, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- $\kappa$ B" <u>Curr. Biol.</u> 6(12):1669-1676 (1996)
	*142	Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor (TNFR) Family, Interacts with Members of the TNFR-associated Factor Family and Activates the Transcription Factors NF- $\kappa$ B and AP-1" <u>Journal of Biological Chemistry</u> 272(22):14029-14032 (1997)
	*143	Marsters et al., "Identification of a ligand for the death-domain-containing receptor Apo3" <u>Current Biology</u> 8(9):525-528 (1998)
cu	*144	Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K <sup>+</sup> Channel Currents" <u>Science</u> 255:192-194 (1992)

Examiner

Claus M. Kof

Date Considered

9/20/02

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1134R2C2

Serial No.

09/896,096

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

1646

To Be Assigned

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

CU	*145	Mather, J.P., "Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines" <u>Biol. Reprod.</u> 23:243-252 (1980)
	*146	Mauri et al., "LIGHT, a new member of the TNF superfamily, and lymphotoxin $\alpha$ are ligands for herpesvirus entry mediator" <u>Immunity</u> 8(1):21-30 (Jan 1998)
	*147	Medvedev et al., "Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas- ligand in NK/LAK cell-mediated cytotoxicity" <u>Cytokine</u> 9(6):394-404 (Jun 1997)
	*148	Merrifield, R.B., "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide" <u>J. Am. Chem. Soc.</u> 85:2149-2154 (1963)
	*149	Milstein et al., "Hybrid Hybridomas and Their Use in Immunohistochemistry" <u>Nature</u> 305:537-540 (1983)
	*150	Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996)
	*151	Moretta, A., "Molecular mechanisms in cell-mediated cytotoxicity" <u>Cell</u> 90(1):13-18 (Jul 11, 1997)
	*152	Munson et al., "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems" <u>Analytical Biochemistry</u> 107:220-239 (1980)
	*153	Nagata and Golstein, "The Fas Death Factor" <u>Science</u> 267:1449-1456 (1995)
	*154	Nagata, S., "Apoptosis by Death Factor" <u>Cell</u> 88:355-365 (1997)
	*155	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" <u>EMBO Journal</u> 9:3269-3278 (1990)
CU	*156	Nygren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" <u>The Journal of Histochemistry and Cytochemistry</u> 30(5):407-412 (1982)
	*157	<del>O'Reilly, D., Baculovirus expression-vectors: a laboratory manual, New York:Oxford University Press (1994)</del>
CU	*158	Otsuki et al., "Over-expression of the decoy receptor 3 (Dcr3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients" <u>Clin. Exp. Immunol.</u> 119:323-327 (2000)
	*159	Paborsky et al., "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen" <u>Protein Eng.</u> 3(6):547-553 (1990)
	*160	Pain et al., "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its Use in Enzyme Immunoassays" <u>Journal of Immunological Methods</u> 40:219-230 (1981)
	*161	Pan et al., "An Antagonist Decoy Receptor and a Death-domain Containing Receptor for TRAIL" <u>Science</u> 277:815-818 (1997)
	*162	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL" <u>Science</u> 276:111-113 (1997)
	*163	Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids" <u>European Journal of Haematology</u> 41:414-419 (1988)
CU	*164	Pennica et al., "Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin" <u>Nature</u> 312:724-729 (1984)

Examiner

Claus M. Roff

Date Considered

9/20/02

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JAN 22 2002

TECH CENTER 1600/2900

USCOMM-DC 80-398.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1134R2C2

Serial No.

09/896,096

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group 1646

To Be Assigned

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

cu	*165	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)
	*166	Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992)
cu	*167	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" <u>Nature</u> 325:593-597 (1987)
	*168	<del>Remington's Pharmaceutical Sciences, Oslo et al., eds., 16th edition, Mack Publishing Co. (1980)</del>
cu	*169	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)
a	*170	Ruppert et al., "Cloning and Expression of Human TAF <sub>II</sub> 250: a TBP-associated Factor Implicated in Cell-cycle Regulation" <u>Nature</u> 362:175-179 (1993)
	*171	<del>Sambrook et al., Molecular Cloning: A Laboratory Manual, Second edition, New York: Cold Spring Harbor Laboratory Press (1989)</del>
	*172	<del>Samter et al., Samter's Immunological Diseases, 5th edition, Boston: Little, Brown and Company Vol. I &amp; II (1995)</del>
cu	*173	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (1990)
cu	*174	Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruction Mediated by Cytotoxic T-cell Lines, Lymphotoxin-secreting Helper T-cell Clones, and Cell-free Lymphotoxin-containing Supernatant" <u>Proc. Natl. Acad. Sci. USA</u> 83:1881-1885 (1986)
	*175	<del>Scopes, R., Protein Purification, New York: Springer-Verlag (1982)</del>
cu	*176	Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor $\alpha$ Inhibitor" <u>Journal of Biological Chemistry</u> 264:11966-11973 (1989)
	*177	Shaw et al., "A General Method for the Transfer of Cloned Genes to Plant Cells" <u>Gene</u> 23:315-330 (1983)
	*178	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)
	*179	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (1997)
	*180	Skinner et al., "Use of the Glu-Glu-Phe C-terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins" <u>Journal of Biological Chemistry</u> 266:14163-14166 (1991)
	*181	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1019-1023 (1990)
	*182	Smith et al., "Cardiac Glycoside-Specific Antibodies in the Treatment of Digitalis Intoxication" <u>Antibodies in Human Diagnosis and Therapy</u> pps. 365-389 (1977)
	*183	Smith et al., "T2 Open reading frame from the Shope fibroma virus encodes a soluble form of the TNF receptor" <u>Biochem. &amp; Biophys. Res. Comm.</u> 176:335-342 (1991)
cu	*184	Sojar et al., "A Chemical Method for the Deglycosylation of Proteins" <u>Archives of Biochemistry &amp; Biophysics</u> 259(1):52-57 (1987)

Examiner

*Chen M. Lee*

Date Considered

9/20/02

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1134R2C2

Serial No.

09/896,096

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

1646  
To Be Assigned

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

an	*185	Sompayrac et al., "Efficient infection of monkey cells with DNA of simian virus 40" <u>Proc. Natl. Acad. Sci. USA</u> 78(12):7575-7578 (Dec 1981)
u	*186	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" <u>EMBO Journal</u> 8(5):1403-1410 (1989)
	*187	<del>Stewart et al., "Solid-Phase Peptide Synthesis," San Francisco, CA:W.H. Freeman Co. (1969)</del>
an	*188	Stinchcomb et al., "Isolation and Characterisation of a Yeast Chromosomal Replicator" <u>Nature</u> 282:39-43 (November 1, 1979)
	*189	Strand et al., "Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells --a mechanism of immune evasion?" <u>Nature Medicine</u> 2(12):1361-1366 (Dec 1996)
	*190	Suda et al., "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family" <u>Cell</u> 75:1169-1178 (1993)
	*191	Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> 121:210-228 (1986)
	*192	Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necrosis Factor Receptors Type 1 and Type 2" <u>Immunogenetics</u> 37:199-203 (1993)
	*193	Thimmappaya et al., "Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection" <u>Cell</u> 31(3 Pt 2):543-551 (Dec 1982)
	*194	Thomas and Capecchi, "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells" <u>Cell</u> 51:503-512 (1987)
	*195	Thomas, P., "Hybridization of Denatured RNA and Small DNA Fragments Transferred to Nitrocellulose" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5201-5205 (September 1980)
	*196	Thotakura and Bahl, "Enzymatic Deglycosylation of Glycoproteins" <u>Meth. Enzymol.</u> 138:350-359 (1987)
	*197	Traunecker et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells" <u>EMBO Journal</u> 10(12):3655-3659 (1991)
	*198	Tschumper and Carbon, "Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene" <u>Gene</u> 10:157-166 (1980)
	*199	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" <u>Virology</u> 184:370-382 (1991)
	*200	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the Shope fibroma virus genome" <u>Virology</u> 160:20-30 (1987)
	*201	Urlaub and Chasin, "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity" <u>Proc. Natl. Acad. Sci. USA</u> 77(7):4216-4220 (July 1980)
	*202	Van Solingen et al., "Fusion of Yeast Spheroplasts" <u>J. Bact.</u> 130:946-947 (1977)
	*203	Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)
an	*204	Wagner et al., "Transferrin-polycation conjugates as carriers for DNA uptake into cells" <u>Proc. Natl. Acad. Sci.</u> 87:3410-3414 (1990)

Examiner

Clare M. Lee

Date Considered

9/20/02

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1134R2C2

Serial No.

09/896,096

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

1646  
~~To Be Assigned~~

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Can	*205	Welcher et al., "Nerve growth factor binding domain of the nerve growth factor receptor" <u>Proc. Natl. Acad. Sci. USA</u> 88:159-163 (1991)
	*206	Wells et al., "Cassette Mutagenesis: an Efficient Method for Generation of Multiple Mutations at Defined Sites" <u>Gene</u> 34(2-3):315-323 (1985)
	*207	Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin" <u>Philos. Trans. R. Soc. London Ser A</u> 317:415-423 (1986)
	*208	Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" <u>Immunity</u> 3:673-682 (1995)
	*209	Wong et al., "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells" <u>Journal of Biological Chemistry</u> 272(40):25190-25194 (Oct 3, 1997)
	*210	Wu et al., "Receptor-mediated in vitro gene transformation by a soluble DNA carrier system" <u>Journal of Biological Chemistry</u> 262(10):4429-4432 (1987)
	*211	Yan and Chao, "Disruption of Cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding" <u>Journal of Biological Chemistry</u> 266:12099-12104 (1991)
	*212	Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor" <u>Journal of Experimental Medicine</u> 169:1747-1756 (1989)
	*213	Yu, K. et al., "A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses light-mediated apoptosis" <u>J. Biol. Chemistry</u> 274(20):13733-13736 (1999)
	*214	Zamecnik et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA" <u>Proc. Natl. Acad. Sci.</u> 83:4143-4146 (1986)
	*215	Zheng et al., "Induction of Apoptosis in Mature T Cells by Tumor Necrosis Factor" <u>Nature</u> 377:348-351 (1995)
	*216	Zola, "Using Monoclonal Antibodies: Soluble Antigens" <u>Monoclonal Antibodies: A Manual of Techniques</u> , CRC Press, Chapter 6, pps. 147-158 (1987)
Can	*217	Zoller and Smith, "Oligonucleotide-directed Mutagenesis Using M13-derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA" <u>Nucl. Acids Res.</u> 10(20):6487-6500 (1982)

RECEIVED

JAN 22 2002

TECH CENTER 1600/2900

Examiner

*Alan M. K...*

Date Considered

9/20/02

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1134R2C2

Serial No.

09/896,096

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

28 Jun 2001

Group

1646

~~To Be Assigned~~

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
am	1	2002/0068064	06.06.02	Shen-Chih et al.			

RECEIVED  
AUG 27 2002  
TECH CENTER 1600/2900

Examiner

C. M. H. K.

Date Considered

9/20/02

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.